Following a spate of large-scale pharma investments in the U.S. last year, German conglomerate Bayer is advancing its own plans to expand in America, in a move the company is framing as the ...

Eli Lilly’s Jaypirca, the first noncovalent BTK inhibitor, has won FDA approval for the first-line treatment of chronic ...

Already sharing the load on two biosimilar assets, Teva Pharmaceutical and Samsung Bioepis have elected to take their ...

In three deals each worth $2 billion or more, AstraZeneca is investing in Summit Therapeutics with a focus on ivonescimab and ...

With GLP-1s paving the way, a consumer shift is happening across markets for certain branded pharmaceuticals. | With GLP-1s ...

Pfizer is making moves on the dermatology and wider immunology fronts, detailing two phase 3 wins for its oral Janus kinase inhibitor, Litfulo, and a promising phase 2 update for its investigationa | ...

Genentech is turning up the volume on breast cancer conversations in its “About Damn Time” campaign with Breastcancer.org and ...

While Foundayo’s insulin-matching potential in type 2 diabetes had been established in a topline readout earlier this year, ...

Come year’s end, more than 100 Novo employees reporting to the Danish drugmaker’s outpost in Plainsboro, New Jersey, will be ...

The start-up, which deploys unmanned, reusable rockets into Earth’s low-orbit, secured another $251 million in a series D ...

In Milan this week, Novo and Eli Lilly took the stage at the European Association for the Study of Diabetes 2026 meeting with ...

Real Chemistry has created an artificial intelligence-enabled platform to improve a manual, fragmented stage of the ...